**Company Overview**

**Industry Sector:** Nanopharmaceutical

**Company Overview:** Nanoparticle Biochem Inc (NBI) was established through groundbreaking original discoveries on the design and development of various types of metallic and radioactive nanoconjugates. NBI utilizes these nanoconjugates to derive sophisticated cancer therapy products to ultimately help the patient community, directly or indirectly, in alleviating pain and suffering. NBI's niche in radioactive nanoparticulate technology has allowed the development of sophisticated nanoparticle based nanoradiopharmaceutical agents for applications in the field of oncology.

**Target Market(s):** Major radiation oncology hospitals worldwide.

---

**Key Value Drivers**

**Technology:** Nanoparticle Biochem, Inc (NBI) has developed a radioactive gold nanoconstruct-based therapeutic agent, S-NBI-29, for treating inoperable prostate cancer. In a mouse model, average reduction in tumor size reached 82%, three weeks after single dose of S-NBI-29. Phase I level clinical trials in dogs with prostate tumors showed reduction of tumor size up to 52%. Safety studies in mice and dogs showed no significant toxicity.

**Competitive Advantage:** NBI is uniquely positioned in the nanopharmaceutical industry with definite competitive advantages. S-NBI-29 is the first injectable liquid nano-brachy agent and is expected to serve as highly efficient and non-toxic alternative for implantable radioactive devices for treating prostate tumors. A single, CT guided injection of S-NBI-29 delivers a high therapeutic payload and uniformly distributed radioactivity within the tumor, thereby increasing the therapeutic efficacy several fold compared with traditional radiotherapy. NBI has filed two patent applications on this technology: 13/293,827 and 12/283,935.

**Plan & Strategy:** seeking a strategic partner

---

**Management**

**Leadership:**
- Henry W White, President and CEO
- Raghuraman Kannan, Chief Strategy Officer
- Anandhi Upendran, Director of Research
- Kattesh V Katti, Vice President
- Suzan Anne Moser–Director of Clinical Affairs

**Scientific Advisory Board:**
- Wynn Volkert, Ph.D.: Curators Professor of Radiology Biochemistry at the University of Missouri
- Carl Freter, MD Ph.D.: Professor of Hematology and Oncology, University of Missouri
- Cathy S Cutler, Ph.D: Research Professor, Missouri University Research Reactor, University of Missouri.

---

**Product**

**Product Pipeline**

<table>
<thead>
<tr>
<th>Radiopharmaceuticals</th>
<th>Discovery</th>
<th>Pre-clinical Mice</th>
<th>Pre-clinical Dogs</th>
<th>Pre-IND</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-NBI-29: Radioactive gold for prostate tumor therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S-NBI-70: Targeted radioactive gold for prostate tumor therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Nanopharmaceuticals**

- GNR-29: Gold nanorod for X-ray CT imaging
- NBI-90: Targeted nanoparticles for breast tumor therapy